Northern Dynasty Minerals Ltd. stock falls amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy NAK?
Source: F-10
Northern Dynasty Minerals Ltd. saw a significant decline of 7.52% as it crossed below its 5-day SMA, reflecting broader market trends.
The stock's drop is attributed to sector rotation, as the Nasdaq-100 and S&P 500 indices fell by 1.11% and 0.54%, respectively, indicating a general weakness in the market. This decline in the broader market has negatively impacted investor sentiment towards mining stocks, including Northern Dynasty.
As market conditions remain challenging, investors may be cautious about entering positions in mining stocks, which could lead to further volatility in Northern Dynasty's stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAK
Wall Street analysts forecast NAK stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.480
Low
2.50
Averages
2.50
High
2.50
Current: 1.480
Low
2.50
Averages
2.50
High
2.50
About NAK
Northern Dynasty Minerals Ltd. is a Canada-based mineral exploration and development company based in Vancouver. The Company’s principal business activity is the exploration of mineral properties. The Company’s principal asset, owned through its wholly owned subsidiary, Pebble Limited Partnership, is a 100% interest in a contiguous block of about 1,840 mineral claims in Southwest Alaska, including the Pebble deposit, located about 200 miles from Anchorage and 125 miles from Bristol Bay. The Pebble Partnership is the proponent of the Pebble Project. The deposit lies entirely within the Lake and Peninsula Borough, approximately 23,782 square miles of land. The deposit is a Copper-Gold-Molybdenum-Silver-Rhenium project. Its subsidiaries include 3537137 Canada Inc., Northern Dynasty Partnership, U5 Resources Inc., Pebble West Claims Corporation, and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Northern Dynasty Minerals regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious governance concerns.
- Regulatory Impact: On February 17, 2026, the U.S. Department of Justice filed a court brief supporting the Environmental Protection Agency's veto of Northern Dynasty's proposed Pebble Mine, indicating a strong governmental stance on environmental protection.
- Stock Price Plunge: Following the DOJ brief, Northern Dynasty's stock price fell by $0.80, or 39.41%, closing at $1.23 per share on February 18, 2026, reflecting market pessimism regarding the company's future prospects.
- Potential Legal Consequences: The investigation and stock price decline may expose Northern Dynasty to significant liability, further impacting its financing capabilities and market trust, posing major challenges for future business development.
See More
- Legal Dispute Escalation: Northern Dynasty Minerals has pushed back against a Department of Justice filing, claiming it contradicts the Final Environmental Impact Statement, with plans to file a court response by April 15, indicating a proactive legal strategy in the Pebble Project dispute in Alaska.
- CEO's Statement: CEO Ron Thiessen emphasized that the company will continue to explore settlement options with the EPA while also seeking a swift court ruling, demonstrating the company's firm stance against the government's position and its desire for a quick resolution to the conflict.
- Potential Implications: Thiessen warned that the government's stance could jeopardize other federal permits, particularly concerning Clean Water Act permitting volumes, highlighting the broader implications of this case on mining development and potential ripple effects on future projects.
- Stock Price Movement: At the time of publication, Northern Dynasty Minerals shares fell 4.95% to $1.25, reflecting market concerns regarding the company's legal challenges, which could impact investor confidence and future financing capabilities.
See More
- Stock Price Plunge: Northern Dynasty Minerals (NAK) saw a dramatic 37.6% drop in its stock price during Wednesday's trading, reaching its lowest point in over four months, primarily due to the U.S. Department of Justice filing a court brief in Alaska supporting the EPA's veto of its Pebble mining project.
- Project Development Blocked: Despite the company's executives claiming government support for Alaskan energy development, the EPA chose to uphold the Obama-Biden veto, highlighting the ongoing local opposition and protracted review process that the project faces.
- Significant Resource Potential: The Pebble mine is touted as one of the world's largest copper-gold-molybdenum resources, with a forecasted production of 6.4 billion pounds of copper, 7.4 million ounces of gold, and 300 million pounds of molybdenum over 20 years, yet it faces major environmental challenges due to its location in the Bristol Bay watershed.
- Economic Study Forecast: A 2023 economic study predicts the Pebble mine will yield 37 million ounces of silver and 200,000 kilograms of rhenium, but the EPA's 2023 decision to block mine waste storage under the Clean Water Act effectively ends the project, underscoring the regulatory hurdles the company must navigate.
See More
- EPA Veto Impact: The Environmental Protection Agency (EPA) exercised its rare authority under Section 404(c) of the Clean Water Act to veto Northern Dynasty's Pebble Project, citing irreparable harm to the Bristol Bay salmon fishery, which triggered panic among investors.
- DOJ Supports Veto: The Department of Justice (DOJ) filed a legal brief officially defending the EPA's veto, indicating that the government is not backing down from the case, leading to a collapse of investor hopes for a political pivot and a subsequent stock price drop.
- Stock Price Volatility: Northern Dynasty's stock experienced extreme volatility, plummeting by as much as 45% during trading on Wednesday, with trading volume exceeding 44 million shares by midday, reflecting strong market reactions, and the stock was down to $1.27 at publication, marking a five-month low.
- CEO's Shock Statement: CEO Ron Thiessen expressed shock that the administration continues to defend the veto despite its pro-mining rhetoric, indicating that this legal deadlock will lead to a prolonged legal battle rather than a quick settlement.
See More
- Strong Earnings Report: Palo Alto Networks reported fiscal Q2 revenue of $2.59 billion, surpassing analyst expectations of $2.58 billion, indicating robust performance in the cybersecurity sector despite a challenging market environment.
- Earnings Beat: The company posted adjusted earnings of $1.03 per share, exceeding analyst estimates of 94 cents, demonstrating its continued profitability amidst fierce market competition.
- Guidance Downgrade: Palo Alto lowered its full-year adjusted earnings guidance from a range of $3.80 to $3.90 per share to a new range of $3.65 to $3.70, below the market estimate of $3.86, which may impact investor confidence.
- Stock Price Volatility: In pre-market trading, Palo Alto's shares fell 7.5% to $151.20, reflecting the market's negative reaction to the lowered guidance, potentially leading to subdued investor sentiment in the short term.
See More
- Clinical Trial Results: Sarepta Therapeutics reported significant three-year results from the EMBARK study, showing that patients treated with Elevidys demonstrated statistically significant efficacy in motor function assessments, leading to a 9.8% stock price increase to $23.20, indicating enhanced competitiveness in Duchenne muscular dystrophy treatment.
- Positive Market Reaction: Following the release of favorable clinical data, there was a surge in demand for Sarepta's shares, reflecting investor optimism about the biopharmaceutical sector's outlook, which may attract more capital into the industry.
- Industry Impact: Sarepta's success could inspire other biopharmaceutical companies to increase investments in rare disease research and development, thereby fostering innovation and growth across the sector.
- Investor Confidence Boost: The success story of Sarepta may bolster investor confidence in biotech stocks, particularly as market conditions continue to favor increased focus on the healthcare sector.
See More








